通过循环林D1剥离来对乳腺癌进行特定的保护
Q Yu1, Y Geng, P Sicinski
1Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Nature
|June 29, 2001
概括
缺乏环素D1的小鼠抵抗了由neu和ras瘤基因驱动的乳腺癌,而不是其他人. 这表明cyclin D1对于neuras驱动的乳腺瘤至关重要,这表明潜在的向治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 乳腺癌是女性的主要恶性瘤.
- 细胞循环调节剂cyclin D1的过度表达在乳腺癌中很常见.
- 环素D1在细胞循环进展中起着至关重要的作用.
研究的目的:
- 调查环林D1在乳腺癌发展中的作用.
- 为了确定环素D1缺乏是否会对瘤基因诱导的乳腺瘤产生抗性.
- 探索特定的致癌途径对环素D1.1的依赖性.
主要方法:
- 基因向被用来产生缺乏环素D1的小鼠.
- 乳腺瘤是使用neu和ras瘤基因诱导的.
- 对其他致癌途径 (c-myc,Wnt-1) 的敏感性在缺乏环素D1的小鼠中进行了评估.
主要成果:
- 缺乏环素D1的小鼠对由neu和ras瘤基因诱导的乳腺癌具有抗性.
- 缺乏cyclin D1的小鼠的乳腺上皮仍然对由c-myc或Wnt-1驱动的致癌途径敏感.
- 发现Neu-Ras通路在乳腺上皮细胞转化方面依赖于cyclin D1.
结论:
- 环素D1对于乳腺上皮细胞通过Neu-Ras通路恶性转化至关重要.
- 向cyclin D1可能为具有激活Neu-Ras通路的人类乳腺癌提供一种特定的治疗策略.
- 这些发现突显了环林D1在瘤发生过程中的特定途径作用.
更多相关视频
12:57X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022
08:16X-ray Visualization of Intraductal Ethanol-based Ablative Infusion for Prevention of Breast Cancer in Rabbit Models
Published on: September 12, 2025
相关概念视频
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
